169 results about "Menopausal Symptom" patented technology

A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause.

Methods and devices are described for electrically stimulating nerves and organs to induce and modulate the production of hormones according to desired hormone production patterns and hormone level patterns to treat gynecological conditions. Such methods and devices may be used to treat or alleviate the symptoms of menopause. In addition, such methods and devices may be used for birth control.

A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an overall decrease in body weight, there is also a decrease in percent body fat. This decrease can be proportionally greater than the overall decrease in body weight. In addition, the treatment has a positive effect on bone turnover and osteogenesis making the vitamin D analog a beneficial treatment for the symptoms of menopause. Various exemplary embodiments of the treatment use the 2-alkylidene derivatives of vitamin D3, such as the 2-alkylidene-19-nor derivatives in both the R and S configurations at carbon-20.

The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.

The disclosure provides compositions comprising liquiritigenin, or derivatives, or prodrugs, useful as estrogen receptor beta selective agonists. The disclosure also provides methods of treating menopausal symptoms, and estrogen-dependent disorders, with said compositions.

Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The present invention relates to a use of bamboo or bamboo extract to prevent or treat symptoms related to decrease of androgen; a composition for androgen agonist comprising bamboo or bamboo extract; a method for preventing or treating symptoms related to decrease of androgen by administering composition for androgen agonist; and a method of preparing composition for androgen agonist. The present composition obtained from natural material can be used as Phyto-androgen for the preventing and treating symptoms of male climacteric without dangerousness according to hormone replacement therapy.

The invention pertains to a composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviating depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate craving, chocolate craving, menopausal complaints, erectile dysfunction and / or reduced libido, The composition contains cocoa or one or more of its pharmacologically active components, and a dopamine D2 receptor agonist.

The present invention relates to novel 11-beta estradiol ester compounds and their use as locally active estrogens in the treatment of the symptomology of menopause and to treat estrogen sensitive cancers, including breast cancer.

The invention provides a traditional Chinese medicine composition, containing the following raw materials: deer product, semen cuscutae, poria extract, polygala tenuifolia, epimedium, fructus psoraleae, Chinese angelica, white paeony root, eucommia bark, Chinese yam, drynaria baronii, cortex acanthopanacis, medlar, prepared rhizome rehmannia, milkvetch root, black-bone chicken, scutellaria baicalensis, rehmannia root, desert cistanche, malt, medicated leaven, bighead atractylodes rhizome, multiflower knotweed root, caltrop, motherwort, liquorice, donkey-hide gelatine, tortoise-plastron glue, swimming bladder and radix achyranthis bidentatae. The traditional Chinese medicine composition can effectively improve female organism immunocompetence, improve menopausal symptoms and realize beautifying effect. The invention also provides a pill or paste containing the traditional Chinese medicine composition.

The invention relates to ginseng milk and a preparation method, belonging to the technical field of health-care drinks. The ginseng milk is the mixture produced by processing ginseng serous fluid, liquid milk, high-quality white sugar, natural sweetener and emulsion stabilizer; and the preparation method is as follows: fresh or preserved ginseng-ginseng serous fluid-material mixing-milky mixed liquid-homogenization-vacuum degassing-removing of upper-layer oxidation liquid and suspended bubbles-ginseng milk initial liquid-ultra-high temperature sterilization-filling and sealing-finished product. The use of the ginseng milk has the effects of preserving health, conditioning insufficiency of qi, blood and body fluid, enhancing immunity, improving female menopausal symptoms, improving male sexual disorders, prolonging life and promising longevity.

This invention relates to a novel soy isoflavone product with high purities and strong biological activities and the method of producing the same from natural soybeans, soybean materials (i.e. tofu dregs, soy molasses) and other plant sources. The method includes three steps consisting of extraction with an organic solvent, hydrolysis using an acid and crystallization using an antisolvent. The procedure is very simple and thus can be easily adapted for large-scale manufacturing. Moreover, the procedure is able to produce a high yield of total isoflavones at a lower cost. HPLC analysis and E-Screen bioassay reveal that the obtained product not only contains a high content of isoflavone aglycones by weight of dry matter but also exhibits strong estrogenic activity toward human cells. Therefore, the product should be efficacious for relieving menopausal symptoms and other estrogen-deficient diseases and can be used in health care supplements or as additives for foods, beverages or cosmetics.

Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.

Embodiments in accordance with the present disclosure are directed to systems and methods for managing hot flashes and / or menopause symptoms. An example system includes sensor circuitry and logic circuitry. The sensor circuitry obtains a physical measurement associated with a user and communicates the physical measurement. The logic circuitry generates a predictive model that indicates a probability of the user having a hot flash at a date and time based on a plurality of input parameters, revises the probability based on the physical measurement using the predictive model, and communicates data indicative of an action in response to the revised probability being outside a threshold, such as providing cooling relief.

Provided herein are a device and method for attenuating posttraumatic stress syndrome, menopause symptoms, dysautonomia and pain by interfering with sympathetic chain signaling, particularly by blocking stellate ganglion conduction.

Androst-5-ene-3β,17βdiol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.

The invention relates to nutritional food with effect of improving health of female in climacteric stage, which comprises (wt%) calcium carbonate 6.25-25.00, soybean protein isolate 6.25-12.50, spirulina 12.50-25.00, soybean isoflavones 1.25-3.12, Angelica sinensis extract 0.62-3.75, rhizoma polygonati extract 0.62-2.50, acanthopanax senticosus extract 5.00-11.25, schisandra chinensis fruit extract 1.25-3.75, vitamin C 0.75-1.25, vitamin E 0.25-0.62, ferric sodium ethylenediamine tetracetate 0.25-1.25, microcrystalline cellulose 64.81-9.61, and polyethylene glycol 0.20-0.40. The inventive food has the effects of improving premenstrual syndrome and female physiological function, retaining normal secretion of hormone, relieving climacteric symptoms, promoting metabolic function of human body and organs, relieving osteopenia, and delaying aging.

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

The invention relates to composite health-care food for improving woman climacteric syndrome and a preparation method thereof. By taking the mass of collagen peptide as reference, 5-40 parts by mass of water-alcohol extract of hop, 5-40 parts by mass of collagen peptide, 5-30 parts by mass of glucosamine, 5-30 parts by mass of chondroitin sulfate, 5-30 parts by mass of calcium citrate, calcium carbonate or calcium lactate, and 0.05-0.3 parts by mass of vitamin D3 or vitamin D are mixed, so that the composite health food containing collagen peptide and used to improve woman climacteric syndrome is obtained and has the dual efficacy of improving woman climacteric syndrome and keeping bone health. The composite health food is capable of improving woman skin status, delaying ageing and the like while being capable of improving climacteric syndrome and controlling osteoporosis.

A Chinese patent medicine for improving the function of female ovary is prepared from wolfberry fruit, safflower and rehmannia root through respectively drying and pulverizing by 20 meshes, proportionally mixing in macropolar extracting liquid, filtering for removing dregs, drying, pulverizing and shaping.

Disclosed are cooling clothing and wipes to alleviate some of the symptoms of menopause, especially hot flashes and night sweats. A wipe is made of a wicking material that does not disintegrate or leave a residue as do current tissues. The wipe carries a cooling agent, such as menthol. When drawn across the skin, the wipe draws perspiration away from the skin while providing a cooling effect. The cooling agent is compatible with make-up. A soothing agent, such as black cohosh, can be added to relax the woman which in turn decreases the severity of the hot flash. Clothing items are made with characteristics similar to those of the wipes. Worn at night, pajamas made according to the present invention relieve menopausal symptoms and allow the woman to sleep with less difficulty. Worn during the day, such clothing relieves such symptoms without drawing attention to the wearer.

The polypeptides in the present invention possess the effects of promoting and inhibiting the secretion of prolactin, and are thus useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion stimulants, which are associated with the secretion of prolactin, such as hypoovarianism, spermatic underdevelopment, menopausal symptoms, hypothyroidism, etc. The polypeptides are useful as drugs for the prevention and treatment of various diseases, in terms of prolactin secretion inhibitors, which are associated with the secretion of prolactin, such as pituitary tumor, diencephalon tumor, menstrual disorder, autoimmune diseases, prolactinoma, sterility, impotence, amenorrhea, lactorrhea, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, lymphoma, Sheehan's syndrome, spermatogenesis disorder, etc.

The invention discloses a healthy soft capsule. The capsule comprises a capsule shell and content, wherein the content is prepared from sheep placenta lyophilized powder, soybean extract, evening primrose oil and pharmaceutically acceptable auxiliaries. The healthy soft capsule can play a role in nourishing ovary and has an excellent oxidation resistance by means of the sheep placenta lyophilized powder with the evening primrose oil and soybean extract, and can be used for remarkably relieving senile plaque, reducing wrinkles, delaying senescence and relieving symptoms of climacterium.

The invention provides a soybean isoflavone and phosphatide compound and its preparing process, wherein the molar ratio of soybean isoflavone and phosphatide is 0.5-2 : 1. The preparing process consists of charging organic solvent with low dielectric constant into the mixture, stirring and mixing, filtering the solvent, finally subjecting the filter liquor to decompression drying or freeze drying.

Compounds of structural formula I as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and / or muscle tissue. These compounds are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporesis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents.

The invention relates to a female health beverage prepared from tea flower and maca powder, and the female health beverage is characterized by comprising the following raw materials by weight: 45-50 parts of fresh tea flower, 15-17 parts of maca powder, 3-5 parts of lemon, 2-4 parts of raw ginger, 12-15 parts of skim milk powder, 20-25 parts of glucose, 10-15 parts of white granulated sugar and 250 parts of water; the female health beverage is unique in flavor and rich in nutrients, has good health care effect, is suitable for women to drink, has excellent effects of detoxifying, resisting aging, enhancing immunity, regulating human hormone secretion, relieving menopausal symptoms, improving sub healthy state, and improving gynecological inflammation.

Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with pre menopause, menopause, and / or post menopause are described herein. These select phytoestrogen formulations are composed only of two or more plant-derived estrogenic molecules and / or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The formulations can be administered enterally, transdermally, transmucosally, intranasally or parenterally. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly / monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.